Diarrhoea is a symptom with several possible causes. For a short, uncomplicated episode, the immediate priority is replacing lost fluid and electrolytes; severe dehydration, blood, intense pain or worsening illness need medical assessment. Confidence: high for dehydration precautions and cause-directed care; insufficient for a universal, independently verified probiotic or supplement recommendation. This guide addresses acute and persistent symptoms. Chronic diarrhoea requires a more detailed diagnostic discussion rather than repeated treatment as a stomach bug.
- The stool pattern, duration and accompanying symptoms help determine what assessment is needed.
- Rehydration treats a major danger; temporarily slowing stools does not identify or remove the cause.
- Blood, severe pain, inability to keep fluids down or signs of dehydration need prompt care.
- Antidiarrhoeal medicines are unsuitable in several situations, including some antibiotic-related or inflammatory illness.
- Maintain nutrition and seek a cause for continuing symptoms; broad food restriction and supplements can delay assessment.
Table of contents
- Evidence summary
- What diarrhoea is
- How it works
- The evidence-based treatments
- Supplement and lifestyle evidence
- What works and what does not
- Risks and side effects
- Important interactions
- Who needs special assessment
- Clinician-led treatment and use
- Animal and in-vitro evidence
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.
| Claim / intervention | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Fluid and electrolyte replacement | NIDDK and NHS clinical education | Public institutional finance; supporting trial finances not all traced | Major care priority; severe dehydration needs clinical treatment. |
| Antidiarrhoeal medicine | NHS suitability and NIDDK care context | Page-level finance incomplete; no independent product comparison | Selected use only; blood, inflammatory illness and antibiotic-related symptoms change suitability. |
| Probiotics | NCCIH research/safety summary | Underlying studies remain financially unclassified here | No universal independent efficacy recommendation or transfer between strains and settings. |
| Continuing symptoms | NIDDK diagnostic education | Public institutional accountability, not trial-level clearance | Investigate a cause rather than repeatedly treating an unexplained symptom. |
What diarrhoea is
Diarrhoea usually means loose or watery stools occurring at least three times daily or more frequently than normal for the individual. The change from the usual pattern matters as well as the count. NIDDK describes a typical acute episode as lasting less than a week, persistent symptoms as lasting over two but under four weeks, and chronic diarrhoea as lasting at least four weeks. NIDDK duration categories.
These labels describe a pattern; they are not instructions to wait before seeking help. A person can become seriously unwell early in an episode. Symptoms that recur, interrupt sleep or remain unexplained should be discussed with a clinician, even if they are not continuously present.
Diarrhoea may occur with urgency, cramping, nausea or vomiting. The cause can be an infection, medicine effect or a digestive disorder. Symptoms alone rarely identify a particular germ or establish that food eaten most recently was responsible. NIDDK clinical causes.
How it works
Watery stool removes more fluid and electrolytes from the body than normal stool. If losses exceed replacement, the person becomes dehydrated. Continuing diarrhoea can also interfere with nutrition, depending on the underlying condition. Treatment therefore needs to account for drinking, urine output, food intake and general condition, not only bathroom frequency. NIDDK complications.
Common short-term causes include intestinal viruses, contaminated food and adverse effects of medicines. Antibiotics, magnesium-containing antacids and products containing sugar alcohols can be relevant. A clinician should review the actual medicine list before attributing the symptoms to a supplement or infection. NIDDK acute causes.
When symptoms continue, the range of explanations expands. Infection may persist, or there may be an intolerance, coeliac disease, inflammatory bowel disease, IBS or another digestive problem. A previously familiar symptom does not prove that the current episode has the same cause.
The evidence-based treatments
Clinical care begins with severity assessment and fluid replacement. Oral rehydration solutions contain glucose and electrolytes intended to replace losses. A pharmacist or clinician can help choose an appropriate product. Severe dehydration may require intravenous fluids and hospital treatment. NIDDK hydration care.
Small, frequent sips can be easier to manage when nauseated. Watch whether fluids stay down and whether urination is returning toward normal. The NHS dehydration guidance identifies reduced or dark urine, dry mouth and persistent dizziness as warning signs; improvement in stool frequency alone does not demonstrate adequate rehydration. NHS dehydration assessment.
Testing is selected according to the history and examination. A stool sample can check for infection or other abnormalities; blood tests can assess complications or possible underlying conditions. Not every short, improving episode requires every available investigation. NIDDK selected tests.
Antibiotics or other targeted medicines may be appropriate for particular infections or diseases. They are not interchangeable treatments for all diarrhoea. A clinician needs to decide whether an infection requires specific treatment and whether recent antibiotic exposure changes the assessment. NIDDK cause-directed treatment.
Supplement and lifestyle evidence
An oral rehydration product serves a different purpose from a probiotic or a general “gut repair” supplement. Replacing lost fluid and salts does not require an assumption that the microbiome needs to be reset. Ask what outcome a product is intended to address and whether it could interfere with assessment.
Probiotics differ by organism, strain, preparation and clinical setting. NCCIH describes substantial uncertainty about which preparations help particular people. Evidence about preventing antibiotic-associated diarrhoea cannot automatically be transferred to treatment of a new foodborne illness, chronic unexplained symptoms or every commercial blend. NCCIH preparation-specific limits.
No probiotic efficacy verdict here rests on industry-funded trials, and the studies summarized by government education have not all received a financial audit. That is a limit on the independent conclusion, not proof that every preparation is ineffective. A commercial “clinically studied” label alone does not resolve the question.
Once appetite returns, most people can resume normal food rather than fast or follow a prolonged restrictive diet. Some temporarily find lactose or foods rich in sugar, sugar alcohols or fat worsen symptoms. Food adjustments should preserve nutrition and be reviewed if symptoms continue. NIDDK nutrition guidance.
What works and what does not
Useful progress means the person is keeping fluids down, passing urine, becoming more comfortable and moving toward their usual bowel pattern. A simple record of stool frequency, vomiting, fluids and symptoms can make a clinical conversation clearer. A temporary reduction in urgency is only one part of that picture.
When infection is suspected, protect others. Wash hands with soap and water, clean shared bathroom surfaces and avoid preparing food for other people while ill. The NHS advises staying away from work or school until at least 48 hours after vomiting or diarrhoea has stopped; local workplace, healthcare or food-handling rules may add requirements. NHS infection precautions.
Endoscopy or breath testing may be appropriate for selected continuing symptoms, but a test should answer a clinical question. Do not buy a collection of unrelated investigations and assume that each abnormal-looking result explains the illness. NIDDK diagnostic options.
If symptoms persist, repeatedly removing more food groups or trying successive supplements can obscure the pattern. Agree a review point and a plan for reconsidering the cause.
Risks and side effects
Seek emergency care for confusion, unusual difficulty waking, breathing difficulty, cold or markedly discoloured skin, or sudden severe abdominal pain. Dehydration with shock features can be life-threatening. Blood in vomit, coffee-ground-like vomit or concerning green vomit also needs emergency assessment. NHS shock warning signs; NHS emergency symptoms.
Get prompt clinical advice for blood or black tarry stool, high fever, frequent vomiting, severe pain or dehydration. NIDDK recommends early review when adult symptoms exceed two days or stools are very frequent. Do not wait for a duration category to change if the person is deteriorating. NIDDK urgent assessment.
Loperamide should not be taken for severe diarrhoea after antibiotics, an inflammatory bowel flare, constipation or a swollen abdomen. Blood with fever and symptoms lasting beyond 48 hours require medical advice before use. NHS loperamide cautions.
Important interactions
Tell the clinician about prescriptions, over-the-counter medicines and supplements, especially recent antibiotics, laxatives and magnesium-containing products. Bring names and start dates rather than describing everything as a “stomach medicine.” Do not independently stop necessary prescriptions when a side effect is suspected.
People with diabetes, kidney disease, weak immunity or other significant illness may need a specific rehydration product or fluid plan. NIDDK advises discussing oral rehydration use with the doctor in these groups and in older adults. A generic fluid target may not fit the person’s circumstances. NIDDK individual hydration precautions.
A pharmacist should review any proposed antidiarrhoeal product alongside the medication list. The appropriate decision depends on the formulation, suspected cause and patient, not simply whether the product is sold without prescription.
Who needs special assessment
Babies and young children can deteriorate quickly. Seek advice if feeding stops, wet nappies decrease, the child is drowsy or fluid cannot be retained. Continue usual breast milk or formula while following clinical advice; do not weaken formula to treat diarrhoea. NHS infant and child advice.
Pregnancy, age over 65, current antibiotic use and impaired immunity increase concern about complications. Seek early advice rather than relying on adult home-treatment assumptions. NIDDK higher-risk groups.
Probiotics require particular caution in serious illness or impaired immunity. NCCIH reports infection risks and emphasizes close clinical supervision in vulnerable patients. Premature infants should not receive an adult supplement experiment. NCCIH safety limits.
Clinician-led treatment and use
Before the consultation, note when symptoms began, the usual bowel pattern, stool appearance, fever, vomiting, pain and urine changes. Mention recent travel, untreated water, sick contacts, antibiotics or a new medicine. These details help the team decide how urgently to assess the problem.
Ask whether the priority is home rehydration, a stool sample, medicine review or urgent examination. If a short-term symptom medicine is proposed, confirm the situations in which it must be stopped or avoided and when continuing symptoms require another assessment. This guide gives no individual dose or antibiotic regimen.
For ongoing symptoms, agree what the next review will investigate and how nutrition will be protected. Ask how to collect and deliver a stool sample correctly if one is requested. Keep the plan practical enough to follow while unwell, including access to fluids, a toilet and help when needed.
Animal and in-vitro evidence
A laboratory effect on a germ, fermentation or intestinal cells can suggest a research mechanism. It does not establish clinical recovery, safe hydration or benefit from a particular supplement in a person with diarrhoea. Animal and test-tube findings do not contribute to a human treatment verdict here.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 6 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Public NIDDK, NHS and NCCIH education supplies clinical and safety context. Their institutional funding can be traced, but page contributors and every supporting study have not all been financially cleared. The table distinguishes those limits from the credibility of straightforward care information. No corporate efficacy evidence is used to endorse a supplement.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NIDDK: definition and complications | NIH/HHS public institution; federal budget documentation. No page-level commercial sponsor identified; outside-expert financial disclosures not supplied. | United States; NIDDK, Bethesda, Maryland; federal health education. | Tier 1 institutional context; page-level expert independence unverified. | B, provisional — scientific review and public accountability favor accuracy; institutional priorities, simplification and underlying study finances remain limits. |
| NIDDK: symptoms and causes | NIH/HHS public institution; federal budget documentation. No page-level commercial sponsor identified; outside-expert financial disclosures not supplied. | United States; NIDDK, Bethesda, Maryland; federal health education. | Tier 1 institutional context; page-level expert independence unverified. | B, provisional — scientific review and public accountability favor accuracy; institutional priorities, simplification and underlying study finances remain limits. |
| NIDDK: diagnosis | NIH/HHS public institution; federal budget documentation. No page-level commercial sponsor identified; outside-expert financial disclosures not supplied. | United States; NIDDK, Bethesda, Maryland; federal health education. | Tier 1 institutional context; page-level expert independence unverified. | B, provisional — scientific review and public accountability favor accuracy; institutional priorities, simplification and underlying study finances remain limits. |
| NIDDK: treatment | NIH/HHS public institution; federal budget documentation. No page-level commercial sponsor identified; outside-expert financial disclosures not supplied. | United States; NIDDK, Bethesda, Maryland; federal health education. | Tier 1 institutional context; page-level expert independence unverified. | B, provisional — scientific review and public accountability favor accuracy; institutional priorities, simplification and underlying study finances remain limits. |
| NIDDK: eating and nutrition | NIH/HHS public institution; federal budget documentation. No page-level commercial sponsor identified; outside-expert financial disclosures not supplied. | United States; NIDDK, Bethesda, Maryland; federal health education. | Tier 1 institutional context; page-level expert independence unverified. | B, provisional — scientific review and public accountability favor accuracy; institutional priorities, simplification and underlying study finances remain limits. |
| NHS: diarrhoea and vomiting | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | B, provisional — care accountability and clear triage guidance; simplified advice, not a trial-level financial audit. |
| NHS: dehydration | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | B, provisional — care accountability and clear triage guidance; simplified advice, not a trial-level financial audit. |
| NHS: loperamide suitability | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | B, provisional — care accountability and clear triage guidance; simplified advice, not a trial-level financial audit. |
| NCCIH: probiotics and safety | NIH federal agency; NCCIH budget information. Page-level commercial sponsor not named; underlying review/trial funding not exhaustively traced. | United States; NCCIH, Bethesda, Maryland; federal education. | Tier 1 institution; underlying trials unclassified. | B, provisional — public review and explicit uncertainty favor accuracy; an older synthesis does not certify any product or remove trial sponsorship. |
Frequently asked questions
Should I stop eating? Prolonged fasting is generally unnecessary. Resume food as tolerated and obtain advice when nutrition or an infant’s feeding is affected. NIDDK eating guidance.
Does improvement with loperamide establish the cause? No. Slower stools do not establish whether the problem was infectious, medicine-related or caused by another disorder.
Can a stomach bug temporarily change lactose tolerance? Yes, some people have difficulty digesting lactose during recovery. Persistent symptoms need review rather than an automatic permanent dairy ban. NIDDK recovery guidance.
When does this become chronic? NIDDK uses at least four weeks, including symptoms that come and go. That definition does not override urgent warning signs or earlier medical review. NIDDK chronic category.
Sources and funding notes
NIDDK diarrhoea pages were reviewed September 2024. NHS diarrhoea and vomiting guidance is dated December 2023, loperamide suitability April 2024 and dehydration May 2026. Their triage wording differs; this guide favors early clinical advice when symptoms continue or risk factors are present and never uses a time threshold to postpone care for deterioration. Probiotic studies summarized by public education have not all been financially cleared, so no commercial efficacy ranking is offered. This overview is distinct from the planned chronic-diarrhoea diagnostic guide.
- NIDDK: definition and complications — Acute, persistent and chronic categories; September 2024.
- NIDDK: symptoms and causes — Infections, medicines, longer-term causes and assessment thresholds; September 2024.
- NIDDK: diagnosis — History, examination and selected stool, blood, breath or endoscopic tests; September 2024.
- NIDDK: treatment — Hydration and cause-specific clinical care; September 2024.
- NIDDK: eating and nutrition — Return to usual food and temporary intolerance; September 2024.
- NHS: diarrhoea and vomiting — Home care, infection precautions and emergency assessment; December 2023.
- NHS: dehydration — Dehydration recognition and shock emergencies; May 2026.
- NHS: loperamide suitability — Contraindications, age restrictions and pregnancy review; April 2024.
- NCCIH: probiotics and safety — Strain-specific uncertainty and high-risk safety context; supporting trials not financially cleared.
Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
